Current Affairs Topics Quiz Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

TB survivors seek government clarification on continuity of medicines and diagnostic supplies amid global conflict

March 13, 2026 4 min read Social Issues Polity & Governance International Relations GS Paper 2 (Health Government Policies); GS Paper 3 (Science & Technology)
On This Page ▼

What Happened

  • Tuberculosis (TB) survivors and patient advocacy groups sought clarification from the government on the continuity of free TB treatment under the National Tuberculosis Elimination Programme (NTEP).
  • Concerns centred on reports of disruptions in drug supply, diagnostic availability, and nutritional support payments under the Nikshay Poshan Yojana, threatening India's ambitious TB elimination timeline.
  • Patients on long-duration Drug-Resistant TB (DR-TB) treatment — which can last 9–24 months — are particularly vulnerable to treatment interruptions, which risk treatment failure, relapse, and amplification of drug resistance.
  • The clarification sought included assurances on uninterrupted availability of first-line and second-line anti-TB medicines, cash transfers, and nutritional supplements under the programme.
  • The issue is set against India's stated goal of TB elimination by 2025 — a target that health experts acknowledge is unlikely to be met given current incidence trends.

Static Topic Bridges

National Tuberculosis Elimination Programme (NTEP) and India's TB Burden

India carries the world's largest burden of tuberculosis, accounting for over a quarter of global TB cases. The National TB Elimination Programme (NTEP) — formerly RNTCP (Revised National TB Control Programme) — is the Government of India's flagship programme for TB control, funded primarily through the Union Health Ministry and supplemented by Global Fund grants. The programme operates through a network of District TB Centres, Microscopy Centres, and DOTS (Directly Observed Treatment Short-course) providers across the country.

  • India's TB incidence (2023): approximately 199 cases per 100,000 population; the elimination target is 44 cases per 100,000.
  • India's TB mortality (2022): approximately 23 deaths per 100,000; target is 3 per 100,000 by 2025.
  • India achieved a 17.7% decline in TB incidence from 2015 to 2023 — more than double the global average decline of 8.3%.
  • Prime Minister Narendra Modi announced the goal of eliminating TB by 2025 in 2018, making India's target five years ahead of the global Sustainable Development Goal (SDG) target of 2030.
  • The National Strategic Plan (NSP) 2017–2025 guides the programme under four pillars: Detect–Treat–Prevent–Build (DTPB).

Connection to this news: The patient advocates' concern about treatment continuity directly threatens the NTEP's Treat pillar — any disruption in drug supply or nutritional support reduces treatment completion rates and risks generating drug-resistant strains.

Nikshay Poshan Yojana and Nutritional Support for TB Patients

Nikshay Poshan Yojana (NPY) is a Direct Benefit Transfer (DBT) scheme under the NTEP that provides monthly financial support to TB patients for nutritional supplementation. Poor nutrition is a major risk factor for TB — undernutrition weakens immunity and contributes to both infection and disease progression. The scheme recognises that adequate nutrition is as important as drug treatment for successful TB outcomes.

  • NPY provides ₹1,000 per month (recently revised from ₹500) to TB patients throughout their treatment duration.
  • Benefit disbursed: over ₹3,202 crore to approximately 1.13 crore beneficiaries through DBT.
  • Payments are linked to the Nikshay Portal — a web-based patient management system maintained by the Central TB Division, MoHFW, developed with NIC and WHO India support.
  • Energy Dense Nutritional Supplementation (EDNS): introduced for underweight TB patients (BMI < 18.5 kg/m²) during the first two months of treatment; approximately 12 lakh patients targeted.
  • The Nikshay Portal also tracks patient registration, test orders, treatment records, treatment adherence, and case transfers.

Connection to this news: Disruptions in DBT payments or EDNS supply — the specific concerns raised by TB survivors — directly undermine the nutrition-drug synergy that NPY was designed to create, worsening treatment outcomes.

Drug-Resistant TB (DR-TB) and Challenges in Elimination

Drug-Resistant Tuberculosis (DR-TB) — particularly Multi-Drug Resistant TB (MDR-TB, resistant to at least isoniazid and rifampicin) and Extensively Drug-Resistant TB (XDR-TB) — represents a major threat within India's TB epidemic. DR-TB requires longer, more complex, and more expensive treatment regimens and is associated with poorer outcomes. India accounts for a large share of global MDR-TB burden, making DR-TB management central to the elimination goal.

  • MDR-TB treatment duration: typically 9–24 months (shorter "all-oral" regimens now preferred where feasible).
  • NTEP provides free MDR-TB treatment including newer drugs such as Bedaquiline and Delamanid under the conditional access programme.
  • India's new National Guidelines for Management of DR-TB (March 2025): updated treatment algorithms incorporating newer shorter regimens.
  • Treatment interruption risk: even a short drug supply gap can select for further resistance mutations — transforming MDR-TB into XDR-TB.
  • Case detection rate: India has improved; however, a significant "missing TB patients" problem persists in the private sector (only ~50% of TB cases are notified through government channels).

Connection to this news: TB survivors on DR-TB treatment are especially dependent on guaranteed drug supply continuity — a supply disruption at any point in their 9–24 month regimen can be clinically catastrophic and epidemiologically dangerous.

Key Facts & Data

  • India's TB burden: over 25% of global cases (largest in the world).
  • India TB incidence (2023): approximately 199 per 100,000 (elimination target: 44 per 100,000).
  • India TB mortality (2022): approximately 23 per 100,000 (target: 3 per 100,000 by 2025).
  • TB incidence reduction 2015–2023: 17.7% (global average: 8.3%).
  • PM Modi's TB elimination target: by 2025 (SDG target: 2030).
  • NTEP pillars: Detect–Treat–Prevent–Build (National Strategic Plan 2017–2025).
  • Nikshay Poshan Yojana: ₹1,000/month per patient; ₹3,202 crore disbursed to 1.13 crore beneficiaries.
  • DR-TB treatment duration: 9–24 months; uses Bedaquiline and Delamanid.
  • Nikshay Portal: Web-based patient management system by Central TB Division, MoHFW + NIC + WHO India.
  • EDNS: Energy Dense Nutritional Supplementation for underweight patients (BMI < 18.5 kg/m²); ~12 lakh patients targeted.